Techne Corp. (NASDAQ:TECH) Director Roger C. Lucas sold 100 shares of the stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $105.75, for a total transaction of $10,575.00. Following the transaction, the director now owns 4,029 shares in the company, valued at $426,066.75. The sale was disclosed in a filing with the SEC, which is available through this link.

Shares of Techne Corp. (NASDAQ:TECH) traded down 0.701% during trading on Monday, hitting $104.045. 39,186 shares of the company traded hands. The company has a 50-day moving average of $105.13 and a 200-day moving average of $108.05. The stock has a market capitalization of $3.88 billion, a PE ratio of 39.727 and a beta of 0.72. Techne Corp. has a 52-week low of $79.95 and a 52-week high of $117.42.

Techne Corp. (NASDAQ:TECH) last posted its earnings results on Monday, October 31st. The company reported $0.84 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.05. The firm earned $130.60 million during the quarter, compared to analysts’ expectations of $127.47 million. Techne Corp. had a return on equity of 14.40% and a net margin of 18.96%. The firm’s revenue was up 16.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.79 earnings per share. Equities analysts expect that Techne Corp. will post $3.64 EPS for the current year.

Insider Buying and Selling by Quarter for Techne Corp. (NASDAQ:TECH)

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 28th. Investors of record on Monday, November 14th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 1.23%. The ex-dividend date of this dividend is Wednesday, November 9th. Techne Corp.’s payout ratio is 48.85%.

Several analysts have commented on the stock. Robert W. Baird increased their price target on shares of Techne Corp. from $115.00 to $116.00 and gave the company an “outperform” rating in a research report on Thursday, August 18th. Zacks Investment Research lowered shares of Techne Corp. from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th. Finally, Leerink Swann assumed coverage on shares of Techne Corp. in a research report on Thursday, November 10th. They set an “outperform” rating and a $122.00 price target for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $121.00.

A number of large investors have recently bought and sold shares of the company. Societe Generale acquired a new stake in Techne Corp. during the second quarter valued at $1,682,000. Oregon Public Employees Retirement Fund boosted its stake in Techne Corp. by 2.5% in the second quarter. Oregon Public Employees Retirement Fund now owns 12,381 shares of the company’s stock valued at $1,396,000 after buying an additional 302 shares during the last quarter. World Asset Management Inc acquired a new stake in Techne Corp. during the second quarter valued at $204,000. LS Investment Advisors LLC acquired a new stake in Techne Corp. during the second quarter valued at $103,000. Finally, BNP Paribas Arbitrage SA boosted its stake in Techne Corp. by 182.4% in the second quarter. BNP Paribas Arbitrage SA now owns 21,034 shares of the company’s stock valued at $2,372,000 after buying an additional 13,587 shares during the last quarter. Hedge funds and other institutional investors own 97.84% of the company’s stock.

Techne Corp. Company Profile

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

5 Day Chart for NASDAQ:TECH

Receive News & Stock Ratings for Techne Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Techne Corp. and related stocks with our FREE daily email newsletter.